Absorption, Distribution, Metabolism and Excretion of BIA 5-1058

NCT ID: NCT04991181

Last Updated: 2021-08-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-31
• Study Completion Date: 2017-05-24

Brief Summary

the purpose of this study is:

• to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7 Megabecquerel (MBq) of radiocarbon;
• to determine the pharmacokinetics (PK) of total radioactivity (TRA) in plasma and whole blood and to assess the blood-to-plasma ratio;
• to determine the PK of BIA 5-1058 and its metabolites in plasma.

Detailed Description

This was a Phase 1, single-center, open-label, absorption, distribution, metabolism, and excretion study in 8 healthy adult male subjects. Subjects received a single oral dose of 400 mg BIA 5-1058, containing approximately 3.7 MBq (0.08 milliSievert [mSv]) of 14C-BIA 5-1058 as oral capsules. Screening was between Day -21 and Day -2 and confinement period was of one period in the clinic involving drug administration on Day 1, with admission on Day 1 and discharge on Day 15 (336 hours post-dose).

Conditions

Pulmonary Arterial Hypertension

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BIA 5-1058

Capsules; 400 mg; single dose; oral administration.

Group Type: EXPERIMENTAL

400 mg BIA 5-1058

Intervention Type: DRUG

Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).

Interventions

400 mg BIA 5-1058

Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).

Intervention Type: DRUG

Other Intervention Names

Zamicastat

Eligibility Criteria

Inclusion Criteria

1. Gender :male

2. Age :18-65 years, inclusive

3. Body Mass Index (BMI) :18.0-30.0 kg/m2 (BMI [kg/m2] = Body weight [kg] ÷ Height2 [m2]) at screening

4. Subjects, if not surgically sterilized, were willing to use adequate contraception and not donate sperm from admission to the clinical research center until 90 days after discharge on Day 15. Adequate contraception for the male subject (and his female partner) was defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the volunteer, was acceptable

5. All prescribed medication had to be stopped at least 30 days prior to admission to the clinical research center

6. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's Wort) had to be stopped at least 14 days prior to admission to the clinical research center. An exception was made for paracetamol, which was allowed up to admission to the clinical research center

7. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate and "powerdrinks"), commercially available orange juice (because of a potential interaction of radioactivity and vitamin C), grapefruit (juice) and tobacco products from 48 hours prior to admission to in the clinical research center until discharge (Day 15)

8. Normal resting supine blood pressure and pulse showing no clinically relevant deviations as judged by the PI

9. Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the PI

10. All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the PI

11. Willing and able to sign the ICF.

Exclusion Criteria

1. Employee of PRA or the Sponsor

2. Evidence of clinically relevant pathology or a medical history of a major pathology as judged by the PI

3. Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month)

4. Mental handicap (i.e. a general or specific intellectual disability, resulting directly or indirectly from injury to the brain or from abnormal neurological development)

5. History of relevant drug and/or food allergies

6. Smoking more than 5 cigarettes, 1 cigar or 1 pipe daily; the use of tobacco products in the 48 hours (2 days) prior to admission to the clinical research center on Day 1 was not allowed

7. History of alcohol abuse or drug addiction (including soft drugs like cannabis products)

8. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)

9. Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

10. Positive screen for hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV) antibodies or anti human immunodeficiency virus (HIV) 1 and 2 antibodies

11. Participation in a drug study within 90 days prior to drug administration in the current study. Participation in more than 2 other drug studies in the 12 months prior to drug administration in the current study

12. Donation or loss of more than 100 mL of blood within 90 days prior to drug administration. Donation or loss of more than 1.5 liters of blood in the 10 months prior to drug administration in the current study

13. Subject with irregular bowel habits (more than 3 times a day or less than once every 2 days)

14. Strenuous exercise within 96 hours (4 days) prior to admission to the clinical research center

15. Significant and/or acute illness within 5 days prior to drug administration that may impact the safety of the subject, in the opinion of the PI

16. Participation in another ADME study with a radiation burden >0.1 mSv in the period of 1 year prior to screening

17. Exposure to radiation for diagnostic reasons (except dental X rays and plain X rays of thorax and bony skeleton [excluding spinal column]), during work or during participation in a clinical study in the period of 1 year prior to screening

18. Previous use of BIA 5 1058.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Bial - Portela C S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

PRA Health Sciences (PRA) - Early Development Services (EDS)

Groningen, , Netherlands

Countries

Netherlands

Other Identifiers

2015-002407-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BIA-51058-104

Identifier Type: -

Identifier Source: org_study_id